Pricing Log in Create free account
Saturday 17 October 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

299.77 6.47 −2.11%
Market cap
$14.6B
P/E
0.0×
Fwd P/E
29.6×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Charles River Laboratories International, Inc. (CRL) SEC filings, changes and red flags

Red flags

  • Officer departure

    Charles River Laboratories International, Inc. reported the departure of an officer or director

    8-K filed · The filing · sec.gov

  • Impairment

    Charles River Laboratories International, Inc. recorded a goodwill impairment of $165.0 million in fiscal 2025

    10-K filed · The filing · sec.gov

Filings

Form Period Filed What it reports Flags
8-K Sep 24, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 27, 2026 P1I2: 25 added · 5 removed · 34 modified
P2I1A: no comparison — incorporated by reference
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 5, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits Officer departure
10-Q Mar 28, 2026
8-K May 7, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 25, 2026 7.01 Regulation FD disclosure
8-K Feb 18, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-K Dec 27, 2025 1: 9 added · 2 removed · 77 modified
1A: 21 added · 1 removed · 58 modified
7: 21 added · 15 removed · 47 modified 		Impairment
8-K Feb 18, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 13, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure
8-K Jan 8, 2026 5.02 Departure or appointment of directors or officers
8-K Dec 3, 2025 7.01 Regulation FD disclosure
8-K Nov 14, 2025 8.01 Other events
10-Q Sep 27, 2025
8-K Nov 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K/A Sep 12, 2025 5.02 Departure or appointment of directors or officers
8-K Sep 12, 2025 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 28, 2025
10-K Dec 28, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.